Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Investor Presentation

11 Mar 2021 07:00

RNS Number : 8680R
Cambridge Cognition Holdings PLC
11 March 2021
Β 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

Β 

Investor Presentation

Β 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that CEO Matthew Stork and CFO Michael Holton will provide a live investor presentation on Tuesday 23 March at 6.00 p.m. London time. This follows the anticipated release of the Company's preliminary results for the year ended 31 December 2020 at 7:00 a.m. on 23 March 2021.

Β 

The presentation is open to all existing and potential shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.

Β 

Enquiries:

Β 

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

Β 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

cog@investor-focus.co.uk

Β 

Notes to Editors

Β 

About Cambridge Cognition

Β 

Cambridge Cognition is a technology company developing digital products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Β 

For further information visit www.cambridgecognition.com

Β 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word β€œReach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
NRAJMMPTMTTBBPB
Date   Source Headline
18th Oct 20247:00 amRNSDirectorate Change
10th Oct 202412:44 pmRNSBlock Listing Return
12th Sep 202412:38 pmRNSDirectorate change
22nd Aug 20247:00 amRNSInterim Results
20th Aug 20247:00 amRNSNotice of Results
12th Aug 202412:15 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSIssue of Equity and Total Voting Rights
23rd Jul 20247:00 amRNSTrading Update & Board Change
11th Jul 20247:00 amRNSCambridge Cognition secures Innovate UK grant
1st Jul 20244:20 pmRNSHolding(s) in Company
1st Jul 20247:00 amRNSGrant of Options
28th Jun 20241:48 pmRNSResult of AGM & Change of Name of NOMAD & Broker
21st Jun 202411:23 amRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
17th Jun 202412:33 pmRNSResults of GM, Open Offer, TVR and PDMR Dealing
6th Jun 20247:00 amRNSNotice of AGM
31st May 20247:00 amRNSCircular Publication and Notice of General Meeting
30th May 20247:00 amRNSResult of Placing and Subscription
29th May 20244:39 pmRNSProposed Placing, Subscription and Open Offer
1st May 20247:00 amRNSPreliminary Results, Trading Update & Board Change
30th Apr 20247:00 amRNSNotice of Results
23rd Apr 20247:00 amRNSCOG spin-out Monument Therapeutics accesses £1.5m
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.